Systemic lupus erythematosus (SLE) is an autoimmune disorder affecting many systems in the body. Because of the disease's tremendous variety, some researchers believe that it is a syndrome rather than a single disease. One of the most prevalent manifestations of SLE is lupus nephritis (LN). Nearly 40% to 70% of patients with SLE have LN. The manifestations of LN range from asymptomatic urinary findings to nephrotic syndrome and progressive renal impairment. The International Society of Nephrology and the Renal Pathology Society (ISN/ RPS) have indicated that the various LN classes exhibit different natural history and clinical patterns. Subclinical lupus nephritis (SLN) is nephritis diagnosed via renal biopsy despite normal urinalysis. Renal biopsy is the most important procedure to detect renal damage and SLN.
Purpose: Detection of the relationship between the activity of SLE and the histopathology of renal biopsy. Patients and methods: This is a cross-sectional study. It included one hundred Egyptian patients with SLE according to the 2015 ACR/SLICC Revised criteria. SLE Disease Activity Index (SLEDAI) and renal biopsy were done on all patients in addition to the routine investigations.Results: Of the one hundred patients; Nine are males and 91 are females with a mean age ± standard deviation of 32.28 ± 9.59 years. The mean value of SLEDAI was 11.92 ± 3.92. Lupus nephritis (LN) was found in 85 patients (85%) included 5 patients (5%) having class 1, 73 patients (73%) having class 2, and 7 patients (7%) having class3 LN. SLEDAI mean value is directly proportional to the class of LN increasing from 10.6 ± 3.91 in normal cases to 16 ± 3.92 in class III LN. Conclusion:The relationship between the SLEDAI score and the histopathological study of renal biopsy in patients with SLE is strong and significant with a mean value of SLEDAI directly proportional to the class of LN.
Purpose. To assess the effects of phacoemulsification on the corneal endothelium in patients with gout and age-related cataracts. Methods. Eighty-eight patients who underwent uneventful phacoemulsification for age-related cataracts were included in this retrospective comparative study. The patients were divided into two groups: group A included 31 patients with gout and tight control of uric acid levels and group B included 57 patients without gout or any other systemic disease. All patients completed follow-up assessments over 6 months, and the two groups were compared in terms of changes to their specular microscopic values. Results. Both groups showed marked improvement in uncorrected and best-corrected visual acuity at the end of the follow-up period. Corneal endothelial cell loss was more severe in group A than in group B, with a mean difference of 221.35 ± 43.87 in group A and 169.88 ± 52.67 in group B at the sixth month ( p < 0.001). The difference between the two groups in terms of other specular microscopic values did not reach statistical significance. Conclusion. Patients with gout are more prone to corneal endothelial cell damage after phacoemulsification than those without gout. To confirm these results, future studies with a prospective design and longer durations of follow-up are needed.
to assess the safety and efficacy of infliximab in the treatment of uveitis associated with Behcet's disease. Methods: fifty patients with Behcet's related uveitis were included in this prospective comparative study. Cases were divided into 2 groups; group A(25 patients) received infliximab and group B (25 patients) received oral steroids. All cases were followed up to one year. Results: In group A, the mean BCVA (logMAR) improved from 0.48±0.14 at baseline to 0.07±0.12 three months after treatment. Also, the number of cases with grade 0 AC cells increased from 0 before starting treatment to 18 after 3 months. In group B, the mean BCVA (logMAR) improved from 0.47±0.13 at baseline to 0.17±0.15 three months after treatment. Also, the number of cases with grade 0 AC cells increased from 0 before starting treatment to 14 after 3 months. Conclusion: Infliximab is both safe and effective in treating uveitis associated with Behcet's disease. Studies with larger sample size and longer follow-up periods are needed to confirm the results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.